AccutarBio
Accutar Biotechnology Inc. is a U.S.-based clinical stage biotechnology company specializing in artificial intelligence (AI)-empowered drug discovery. The company uses a hybrid approach combining computational drug design with wet lab validation to accelerate and reduce the cost of traditional drug discovery. Accutar develops AI solutions such as ChemiRise, Orbital, Virtual Screen, Intelligent-SAR, and Chemi-Net to enhance drug discovery efforts. Their pipeline includes orally bioavailable chimeric degrader molecules targeting cancers such as ER-positive/HER2-negative breast cancer and metastatic castration-resistant prostate cancer, with FDA Fast Track designations and ongoing clinical trials. The company collaborates with partners like Evommune and has a leadership team with expertise in drug discovery, AI, and clinical operations. Accutar has raised over $100 million from institutional investors and is positioned as a leader in AI-driven drug discovery for oncology and other therapeutic areas.
AccutarBio
Accutar Biotechnology Inc. is a U.S.-based clinical stage biotechnology company specializing in artificial intelligence (AI)-empowered drug discovery. The company uses a hybrid approach combining computational drug design with wet lab validation to accelerate and reduce the cost of traditional drug discovery. Accutar develops AI solutions such as ChemiRise, Orbital, Virtual Screen, Intelligent-SAR, and Chemi-Net to enhance drug discovery efforts. Their pipeline includes orally bioavailable chimeric degrader molecules targeting cancers such as ER-positive/HER2-negative breast cancer and metastatic castration-resistant prostate cancer, with FDA Fast Track designations and ongoing clinical trials. The company collaborates with partners like Evommune and has a leadership team with expertise in drug discovery, AI, and clinical operations. Accutar has raised over $100 million from institutional investors and is positioned as a leader in AI-driven drug discovery for oncology and other therapeutic areas.